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ABSTRACT
The sphingolipid metabolising enzyme Acid Sphingomyelinase (A-SMase) 
has been recently shown to inhibit melanoma progression and correlate inversely 
to tumour grade. In this study we have investigated the role of A-SMase in the 
chemo-resistance to anticancer treatment using mice with melanoma allografts and 
melanoma cells differing in terms of expression/activity of A-SMase. Since autophagy 
is emerging as a key mechanism in tumour growth and chemo-resistance, we have 
also investigated whether an action of A-SMase in autophagy can explain its role. 
Melanoma sensitivity to chemotherapeutic agent cisplatin in terms of cell viability/
apoptosis, tumour growth, and animal survival depended directly on the A-SMase 
levels in tumoural cells. A-SMase action was due to inhibition of autophagy through 
activation of Akt/mammalian target of rapamycin (mTOR) pathway. Treatment of 
melanoma-bearing mice with the autophagy inhibitor chloroquine restored sensitivity 
to cisplatin of tumours expressing low levels of A-SMase while no additive effects 
were observed in tumours characterised by sustained A-SMase levels. The fact that 
A-SMase in melanomas affects mTOR-regulated autophagy and plays a central role in 
cisplatin efficacy encourages pre-clinical testing on the modulation of A-SMase levels/
activity as possible novel anti-neoplastic strategy.
INTRODUCTION
Melanoma is a high-grade, poorly differentiated 
malignant tumour of the melanocytes that hesitates 
frequently in the metastatic stages and accounts for most 
of the skin cancer related deaths [1-3]. Whereas thin 
melanomas have an excellent prognosis after sufficient 
surgical treatment, melanoma disease in advanced stages 
is still a therapeutic challenge despite the large number 
of chemotherapeutic regimens so far developed [4-8]. 
Single drug chemotherapy is in many cases ineffective 
and combinations of chemotherapeutic drugs have shown 
response rates only marginally higher, and at the cost 
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of systemic toxicity [4-8]. New targeted therapies and 
immunotherapies have been recently approved; these show 
better efficacy and have supplanted chemotherapy as first- 
and second-line therapy [7-13]. Since melanoma cells 
eventually become resistant also to these novel therapies, 
the quest for novel, more effective and possibly less toxic 
approaches is still open.
Autophagy, a homeostatic proteolytic system 
of the cell with a role in the removal of proteins, 
aggregates and organelles within the lysosome [14-17], 
is a crucial determinant of the melanoma sensitivity 
to chemotherapeutic drugs [18-25]. The mechanism 
regulating autophagy impact on drugs efficacy still needs 
to be fully clarified. Such an information would help 
designing new strategies for melanoma treatment.
The sphingolipid metabolising enzyme Acid 
Sphingomyelinase (A-SMase) contributes to apoptotic 
death of tumour cells and is important in determining 
tumour sensitivity/resistance to antineoplastic treatments, 
including cisplatin, one of the most potent agents with 
clinical activity against solid tumours [26-36]. We recently 
found that A-SMase actually contributes to determine 
the malignant phenotype of melanoma cells in vitro and 
in vivo in terms of tumour progression, invasiveness 
and metastatic capacity. In addition, A-SMase levels of 
expression correlated with melanoma grade in human 
biopsies [37, 38]. Tumours expressing low A-SMase 
levels displayed high levels of inflammatory factors and 
an immune-suppressive/pro-tumoural microenvironment. 
Overexpression of A-SMase induced a high recruitment 
at the tumour site of effector immune cells with an anti-
tumoural function [37, 38]. Interestingly A-SMase and 
sphingolipids appear to regulate autophagy, especially the 
process of lysosome trafficking and fusion [39, 40]. 
In this study we have investigated the role of 
A-SMase on autophagy using mice with melanoma 
allografts and mouse and human melanoma cells differing 
in terms of expression/activity of A-SMase. We found 
that the inhibition of autophagy by A-SMase determines 
tumour response to cisplatin in a mechanism involving 
activation of the Akt/mammalian target of rapamycin 
(mTOR) pathway. These results support the importance of 
A-SMase as a therapeutic prospective target in melanoma 
progression.
RESULTS
Chemo-resistance to cisplatin is inversely 
proportional to A-SMase levels
To assess whether A-SMase is involved in in vivo 
chemo-resistance of melanoma to cisplatin we generated 
highly tumourigenic mouse B16 melanoma allografts. 
To this end we used two cell clones B16-W6_scr and 
B16-W6_pSIL10 already characterised for tumourigenic 
potential and A-SMase activity: B16-W6_pSIL10 shows 
significantly lower expression/activity of A-SMase than 
B16-W6_scr and significantly higher tumour-inducing 
potential [38]. Allografts were obtained by injecting 
sub-cutaneously either cell clone. When tumour was 
established, cisplatin was injected intraperitoneally. 
Cisplatin induced a significant decrease in the tumour 
volume of B16-W6_scr transplants but not of B16-W6_
pSIL10 tumours (Figure 1A-1B). Consistently, cisplatin 
significantly imcreased the survival of B16-W6_scr-
injected mice (median of survival: B16-W6_scr = 27 days, 
B16-W6_scr + cisplatin = 35 days), while only marginally 
increasing that of B16-W6_pSIL10-injected mice (median 
of survival: B16-W6_pSIL10 = 23.5 days, B16-W6_
pSIL10 + cisplatin = 26 days) (Figure 1C-1D). Cisplatin-
treated B16-W6_pSIL10 tumours showed significantly 
less DNA fragmentation, detected via TUNEL staining, 
than B16-W6_scr tumours (Figure 1E), in keeping with 
the notion that A-SMase-dependent chemo-resistance to 
cisplatin may involve sensitivity to apoptosis [35]. 
We then examined the effects of cisplatin on the 
viability of melanoma cells. B16-W6_scr and B16-W6_
pSIL10 cells were cultured for 16 h in the absence or 
presence of increasing concentrations of cisplatin, before 
an MTT assay. As shown in Figure 2A, cisplatin caused 
a concentration-dependent reduction of basal absorbance 
with a significantly lower potency (0.8 log units; p < 
0.0001) in B16-W6_pSIL10 (pEC
50
: 4.6 ± 0.03) versus 
B16-W6_scr (pEC
50
: 5.4 ± 0.03) cells. Of importance 
cell viability correlated with A-SMase activity. Cisplatin 
at 10 μg/ml (a concentration around EC
50
) significantly 
increased A-SMase activity in B16-W6_scr cells but not 
in B16-W6_pSIL10 cells (Figure 2B). Apoptosis was then 
analysed by flow cytometry of Annexin V+/propidium 
iodide (PI)− and Annexin V+/PI+ cell fractions, markers 
of early and late apoptotic stages, respectively. The 
apoptotic effects of cisplatin were significantly increased 
in B16-W6_scr when compared to B16-W6_pSIL10 cells 
(Figure 2C). The exogenous addition of human A-SMase 
(2.0 units/ml) [35, 38] to B16-W6_pSIL10 cells restored 
in full their sensitivity to cisplatin. Since A-SMase is 
an acidic pH optimum SMase, which has been shown 
to enter cells via endocytosis becoming active in acidic 
compartments, we also treated mouse melanoma cells 
with bacterial A-SMase, which activity has neutral pH 
optima and is used to hydrolyse sphingomyelin localised 
at the plasma membrane [41]. Exogenously added 
bacterial A-SMase (0.3 units/ml) [42] in B16-W6_pSIL10 
cells had no effect on cisplatin-induced apotosis, thus 
indicating an intracellular action of A-SMase instead 
that a mechanism confined only to cell (Supplementary 
Figure 1). Pharmacological inhibition of A-SMase by 
amitriptyline (5 µM, 1 h before cisplatin treatment), a 
widely used lysosomotropic molecule that induces loss 
of A-SMase [43], significantly decreased the percentage 
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Figure 1: Chemo-resistance to cisplatin in vivo is inversely proportional to A-SMase levels. C57BL/6 mice (n = 8) were 
injected in the right flank with B16-W6_scr (A and C) and B16-W6_pSIL10 (B and D) cells. When tumours where palpable cisplatin (4 mg/
kg) or vehicle was injected intraperitoneally three times every other day. A.-B. Tumour growth was monitored by measuring tumour volume 
(mm3) every 2-3 days. Statistical significance *p < 0.05, **p < 0.01, and ***p < 0.001 vs untreated mice. C.-D. Kaplan-Meier survival curve 
of animals. E. Left panels: representative fluorescence micrographs of TUNEL and DAPI staining in B16-W6_scr and B16-W6_pSIL10 
tumours (500 mm3 volume) excided from mice injected with cisplatin. Scale bar: 100 µm; Right panel: quantitative analysis of TUNEL 
staining (n = 3). Values are expressed as integrated optical density (IOD). Statistical significance **p < 0.01 vs B16-W6_scr + cisplatin.
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Figure 2: Chemo-resistance to cisplatin in vitro is inversely proportional to A-SMase levels. A. Dose-response curves of 
the effects of cisplatin on the viability of B16-W6_scr and B1-W6_pSIL10, as measured by the MTT assay (n = 10). B. Measurement of 
A-SMase activity in B16-W6_scr and B1-W6_pSIL10 cells treated with cisplatin (10 μg/ml, 16 h). Activity was expressed as fold increase 
of untreated cells (n = 5). Statistical significance *p < 0.05 vs untreated B16-W6_scr. C. B1-W6_pSIL10 and B16-W6_scr were cultured 
for 16 h in the absence (UT: untreated) or in the presence of cisplatin (10 μg/ml). B1-W6_pSIL10 and B16-W6_scr were also treated with 
human A-SMase (2.0 units/ml) or amitriptyline (5 µM, 1 h before cisplatin treatment), respectively. Left panels: representative dot plots of 
Annexin V-FITC/PI staining; Right panel: apoptosis quantification expressed as fold increase of total apoptotic cells (Annexin V+/PI− and 
Annexin V+/PI+ cells) compared to their respective UT controls (n = 8). Statistical significance *and § p < 0.05 vs B1-W6_pSIL10 and 
B16-W6_scr, respectively. D. Western blot analysis of cleaved Caspase 3 expression in B16-W6_scr cells cultured for 16 h in the absence 
(UT) or in the presence of cisplatin (10 μg/ml) and cisplatin + amitriptyline (5 µM, 1 h before cisplatin treatment). GAPDH was used as the 
internal standard. The images are representative of results obtained from three experiments.
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of cisplatin-induced B16-W6_scr apoptotic cells at levels 
comparable to B16-W6_pSIL10 cells (Figure 2C), further 
indicating that low A-SMase inhibits cisplatin-induced 
melanoma cell death. These data were then confirmed by 
western blot experiments with an antibody that binds to 
cleaved (active) Caspase 3, an hallmark of apoptosis. In 
particular, as shown in Figure 2D, B16-W6_scr treated 
with cisplatin expressed higher levels of Caspase 3 
activity when compared to untreated cells. Of notice, 
amitriptyline decreased the expression of cleaved Caspase 
3 induced by cisplatin. Similar results were obtained in 
human melanoma cell lines expressing different levels of 
A-SMase protein and enzymatic activity (Supplementary 
Figure 2A). In particular, MTT assay demonstrated 
that Det-mel cells, characterised by low A-SMase [38], 
exhibited a significant rightward shift (0.7 log units; p < 
0.0001) of the cisplatin concentration-dependent curve 
(pEC
50
: 4.5 ± 0.08) when compared with MRS3 cells 
(pEC
50
: 5.2 ± 0.07), characterised by high A-SMase 
[38]. Cisplatin at 10 μg/ml did not induce apoptosis in 
low A-SMase Det-mel cells while the administration of 
exogenous human A-SMase increased significantly the cell 
sensitivity to the chemotherapeutic drug (Supplementary 
Figure 2B). 
A-SMase levels correlate inversely with autophagy
Autophagy contributes to the anticancer efficacy 
of chemotherapy in different types of cancer, including 
melanoma [18-22]. We investigated the relationship 
of A-SMase and autophagy in our model; autophagy 
was assessed by measuring LC3 and p62 protein levels 
by western blot experiments. LC3 is recruited from the 
cytosol and associates with the phagophore early in 
autophagy, while p62 is a cargo of ubiquitinated proteins 
that is degraded lately during the autophagic process and 
accumulates in the presence of defective autophagy [14, 
16, 17]. As shown in Figure 3A, formation of lipidated 
LC3 (the faster migrating band is indicative of completed 
autophagosomes) and reduction of p62 levels was higher 
Figure 3: A-SMase levels affect autophagic process in vitro. A. Upper panels: representative western blot analysis of LC3 lipidation 
and p62 expression in B16-W6_scr and B1-W6_pSIL10 cells. GAPDH was used as the internal standard; Lower panels: densitometric 
analysis of lipidated LC3 (LC3 II) and p62 expression (n = 6-7). B. Left panels: representative western blot analysis of phosphorylated 
Akt, S6 and Ulk1 in B16-W6_scr and B1-W6_pSIL10 cells. The total Akt, S6 and Ulk1 were used as internal standard; Right panels: 
densitometric analysis of phosphorylation levels of Akt, S6, and Ulk1 (n = 4-8). Statistical significance *p < 0.05, **p < 0.01, and ***p < 
0.001 vs B16-W6_scr. 
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in B16-W6_pSIL10 than in B16-W6_scr. Autophagy is 
inhibited by mTOR a protein activated by Akt. mTOR 
increases (directly and indirectly) the phosphorylation of 
autophagy controlling proteins including the S6 ribosomal 
protein (S6) [14, 16, 17, 44] and Ulk1 [45]. We found 
that phosphorylated levels of Akt in B16-W6_pSIL10 
were significantly lower than B16-W6_scr cells and 
accompanied by a lower phosphorylation levels of S6 and 
Ulk1 (Figure 3B).
The inverse correlation of A-SMase levels and 
autophagy was confirmed further in melanoma allografts. 
Ultrastructural analysis of tumours by transmission 
electron microscopy revealed the presence of autophagic 
vacuoles, such as autophagosomes [14-17, 46]. They 
appeared as double or single (rarely)-membrane bounded 
structures sometimes containing small compartments 
or undigested mitochondria, fragments of endoplasmic 
reticulum and multilamellar structures (Figure 4A). 
Membrane tethering sites during autophagy activation is 
driven by inter-organellar micro-domains among which 
are mitochondria-associated endoplasmic reticulum 
membranes (MAMs) [17, 47]. Of notice, MAMs were 
detected in B16-W6_pSIL10 tumours but not in B16-W6_
scr. In line with these results, immunocytochemical 
experiments showed significant lower levels of p62 
staining in B16-W6_pSIL10 tumours when compared 
to B16-W6_scr tumours (Figure 4B), indicative of an 
increased autophagic process. 
Autophagy down-regulation by A-SMase explains 
the response of tumours to chemotherapy with 
cisplatin
Recently, cisplatin was shown to induce an increase 
of lipidated LC3 and autophagosome formation in 
melanoma cells [48]. We investigated whether A-SMase-
induced sensitivity to chemotherapy depended on the 
regulation of autophagy. B16-W6_scr treated with cisplatin 
(16 h, 10 μg/ml) expressed higher levels of lipidated LC3 
and lower levels of p62 when compared to untreated cells 
(Figure 5A). The pharmacological inhibition of A-SMase 
with amitriptyline (5 µM, 1 h before cisplatin treatment) 
further increased lipidated LC3 levels after cisplatin while 
p62 expression was not affected. 
To better support a critical role of A-SMase and 
autophagy in chemo-resistance, in vivo experiments were 
then performed inducing allografts with B16-W6_pSIL10 
and B16-F1_B1A tumour cells; the latter representing 
an A-SMase over-expressing melanoma model [37]. In 
both models A-SMase expression is stable during tumour 
growth [37, 38]. Consistent with the inhibitory role of 
A-SMase in melanoma progression [37, 38] B16-F1_B1A 
tumours grew more slowly than B16-W6_pSIL10 tumours 
(Figure 5B) and exhibited significant lower formation of 
lipidated LC3 (Figure 5C), and up-regulated levels of p62 
(Figure 5C) and phospho-Akt/S6 (Figure 5D). The role of 
autophagy in melanoma progression was then assessed by 
the contemporary injection of tumour bearing mice with 
cisplatin and chloroquine, which inhibits autophagy [18, 
49-53]. As shown in Figure 5E, when both compounds 
were administered, B16-W6_pSIL10 growth-rate was 
significantly reduced. Of interest, B16-F1_B1A tumours 
administered with cisplatin, both in the absence and in the 
presence of chloroquine, displayed similar growth-rate 
which is also comparable to the growth-rate observed in 
the cisplatin and chloroquine-treated B16-W6_pSIL10 
transplants. 
DISCUSSION
A-SMase plays fundamental roles in tumour 
pathogenesis and in their response to treatment in 
different types of cancer [27, 29-35, 40, 54]. The present 
study reveals for the first time that sensitivity to cisplatin 
correlates with the expression/activity of A-SMase and 
is mediated by the intracellular action of this enzyme: 
an inhibitory effect on autophagy which parallels the 
activation of apoptosis. 
Melanoma cells expressing low A-SMase 
displayed marked chemo-resistance to cisplatin in terms 
of cell viability, tumour growth and median survival of 
transplanted animals accompanied by reduced cisplatin-
induced apoptosis; over-expression of A-SMase enhanced 
the antineoplastic effect of irradiation in melanomas [34]. 
Changes in A-SMase activity/levels lead to a dysregulation 
of the autophagy [40]. In particular, A-SMase seems to 
play a role in the autophago-lysosomal degradation and 
an imbalance in A-SMase activity may account for a role 
of A-SMase in the pathogenesis of different diseases 
[40, 55-60]. We have now identified a novel mechanism 
of action of A-SMase in melanomas and found that the 
enzyme down-regulates the autophagic process via 
activation of the mTOR pathway. Sphingolipids play a 
role in autophagy: ceramide and sphingosine 1 phosphate 
are structural and functional components of autophagic 
flux [39, 40, 61-65] and sphingolipid micro-domain 
disturbances occur during defective autophagy [66].
The mTOR-related autophagy was shown to be a 
protective mechanism for melanoma cells [22]. Although 
autophagy has been reported to have opposite roles on 
anticancer treatments, either increasing or decreasing 
their efficacy depending on the cell type [18, 19, 23], a 
general agreement exists that its primary role is to enhance 
cancer cells’ resistance to chemotherapy treatment, and 
inhibition of autophagy may potentiate the re-sensitisation 
of therapeutic-resistant cancer cells to anticancer drugs 
[18, 20, 49, 67]. In this respect, in ongoing clinical trials, 
including those in melanoma, chloroquine is often used in 
combination with chemotherapeutic drugs, radiotherapy, 
some targeted therapies and immunotherapy [18, 21, 68, 
69]. We demonstrate here that chloroquine treatment of 
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Figure 4: A-SMase levels affect autophagic process in vivo. C57BL/6 mice were injected in the right flank with B16-W6_scr 
and B16-W6_pSIL10 cells; tumours were then resected when they reached the volume of 500 mm3. A. Transmission electron microscopy 
showing autophagosomes (black arrows) in B16-W6_scr and B16-W6_pSIL10 tumours. At the lower right of the B16-W6_pSIL10 
micrograph a site of close vicinity between the membranes of endoplasmic reticulum and mitochondrion, i.e. MAM, can be seen. The 
images are representative of results obtained from three experiments. Scale bar = 0.5 µm. B. Left panels: representative fluorescence 
micrographs of p62 and DAPI staining in B16-W6_scr and B16-W6_pSIL10 tumours. Scale bar = 50 µm; Right panel: quantification of 
p62 immunofluorescence staining (n = 3). Values are expressed as integrated optical density (IOD). Statistical significance ***p < 0.001 
vs B16-W6_scr.
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Figure 5: A-SMase levels, authophagy, and chemo-resistance to cisplatin. A. Left panels: representative western blot analysis 
of LC3 lipidation and p62 expression in B1-W6_scr cells cultured for 16 h in the absence (UT: untreated) or in the presence of cisplatin 
(10 μg/ml) and cisplatin + amitriptyline (5 µM, 1 h before cisplatin treatment). GAPDH was used as the internal standard; Right panels: 
densitometric analysis of lipidated LC3 (LC3 II) and p62 expression measured as fold change compared to their respective UT controls (n 
= 3). Statistical significance *p < 0.05 and **p < 0.01 vs UT; § p < 0.05 vs B1-W6_scr + cisplatin. B. C57BL/6 mice (n = 7) were injected 
in the right flank with B16-W6_pSIL10 and B16-F1_B1A cells. Tumour growth was monitored by measuring tumour volume (mm3) every 
2-3 days. Statistical significance ***p < 0.001. C. Left panels: representative western blot analysis of LC3 lipidation and p62 expression in 
B1-W6_pSIL10 and B16-F1_B1A cells. GAPDH was used as the internal standard; Right panels: densitometric analysis of lipidated LC3 
(LC3 II) and p62 expression (n = 7). D. Left panels: representative western blot analysis of phosphorylated Akt and S6 in B1-W6_pSIL10 
and B16-F1_B1A cells. The total Akt and S6 were used as internal standard; Right panels: densitometric analysis of phosphorylation 
levels of Akt and S6 (n = 5-7). Statistical significance *p < 0.05, **p < 0.01, and ***p < 0.001 vs B16-W6_ pSIL10. E. B1-W6_pSIL10 
and B16-F1_B1A allografts were established as in A (n = 7). When tumours where palpable cisplatin alone (4 mg/kg, intraperitoneally) 
and cisplatin + chloroquine (30 mM, in the peritumoural area) were injected and tumour growth monitored. Statistical significance ***p 
< 0.001.
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melanoma-bearing mice enhances the response to cisplatin 
induced by low A-SMase while no effects were observed 
in tumours characterised by sustained A-SMase levels. 
These findings indicate that modulation of autophagy 
induced by A-SMase has a key role in melanoma chemo-
resistance. In particular, the up-regulation of autophagic 
machine which occurs in melanoma cells expressing low 
A-SMase significantly decreases melanoma sensitivity 
to cisplatin, thus suggesting the ability of low A-SMase 
to promote autophagy, and hence tumour cell growth. 
Indeed, constitutive formation of autophagosomes was 
detected in invasive and metastatic melanoma cells [24] 
consistently with the fact that patients with lower number 
of autophagic vacuoles per melanoma cell are more 
responsive to chemotherapy and have better survival [70]. 
Interestingly, autophagy inhibition is required to restore 
cell death in melanoma cells resistant to immunotherapy 
[71]. Accordingly, it has been recently shown that the 
promotion of autophagy facilitates cisplatin resistance 
in melanoma cells [48]. Recently identified autophagy 
inhibitors appear to have the potential to sensitise 
melanomas to first-line therapies [72] and chemotherapy, 
including that with platinum derivatives [73].
Cisplatin represents one of the most successful 
drugs in chemotherapy leading to the discovery of several 
new generations of anticancer compounds which have 
become an invaluable tool in the oncologist’s arsenal. 
Even though it is an “old” drug as the other chemotherapy 
agents, cisplatin continues to find uses in different types 
of cancers, especially as it is synergistic with other agents. 
In particular, in advanced melanoma traditional types of 
chemotherapy, including cisplatin-containing combination 
regimens, are still used although they do not longer 
represent the first-line therapy [4-8]. Cisplatin resistance 
of tumour cells has most often a multifactorial nature and 
involves different cellular mechanisms, as for instance 
the altered expression of proteins in signal transduction 
pathways that control apoptosis/autophagy [18, 74]. With 
respect to chemo-resistance to cisplatin in melanoma cells, 
the role of A-SMase in the modulation of apoptosis and 
autophagy (also induced by cisplatin) led us to hypothesise 
that low A-SMase, as occurs in more aggressive cells [38], 
result in a loss of chemotherapy response through both the 
inhibition of apoptosis and the activation of autophagy. A 
greater understanding of sphingolipid-mediated crosstalk 
between apoptosis and autophagy in melanomas may thus 
be critical for enhancing the chemotherapeutic efficacy 
of these agents [75]. In this respect, recent in vitro data 
emphasize the potential and advantages of manipulating 
sphingolipid system, apoptosis, and autophagy for glioma 
chemotherapy [76]. On the other hand it has been also 
reported that A-SMase overexpression in glioma cells does 
not enhance the anti-glioma activity of chemotherapy [77]. 
In conclusion, A-SMase is an attractive target in 
anti-tumour strategy for melanomas. Our data encourage 
pre-clinical testing on the up-regulation of A-SMase 
levels/activity as possible novel anti-neoplastic strategy 
to circumvent chemo-resistance, enhance the effects of 
chemotherapy and improve clinical outcomes. 
MATERIALS AND METHODS
Animals
Experiments were performed on C57BL/6 female 
mice (Charles River Laboratories, Calco, Italy) at 6-8 
weeks after birth (ca. 20 g body weight). Animals were 
kept in a regulated environment (23 ± 1°C, 50 ± 5% 
humidity) with a 12 h light/dark cycle (lights on at 08.00 
a.m.) and fed ad libitum. All studies were conducted 
in accordance with the Italian law on animal care N° 
116/1992 and the European Communities Council 
Directive EEC/609/86. The experimental protocols were 
also approved by the Ethics Committee of the University 
of Milano. All efforts were made to reduce both animal 
suffering and the number of animals used.
Cell cultures
In agreement with published protocols [37, 38], 
murine melanoma B16 cells and human melanoma 
cells Det-mel and MSR3 were cultured in Iscove’s 
supplemented with 10% heat-inactivated foetal bovine 
serum (FBS), glutamine (200 mM), penicillin/streptavidin 
(100 U/ml), 1% Hepes 1M pH 7.4 and grown at 37°C in 
a humidified atmosphere containing 5% CO2. The low 
expressing A-SMase B16-W6_pSIL10 and the high 
expressing A-SMase B16-F1_B1A clone were generated 
as previously described [37, 38]. Previous results indicated 
that the transfection of B16-W6 cells with the plasmid 
harbouring a shRNA containing a scrambled sequence 
(B16-W6_scr, used as control for B16-W6_pSIL10) or 
B16-F1 cells with the empty vector pEF1/Myc (used as 
control for B16-F1_B1A) did not modify unspecifically 
the cell content/activity of A-SMase, the cell phenotype 
and growing properties [37, 38]. 
Animal handling and allograft tumour model
On day 0, mice were injected sub-cutaneously with 
the tumourigenic dose of 2.5 × 104 B16-W6_scr, B16-W6_
pSIL10, or B16-F1_B1A cells, in the lower-right flank 
[35, 37, 38]. Before the injection, melanoma cells were 
controlled for their levels of expression of A-SMase by 
western blotting. When the syngeneic tumour implantation 
was established (usually 10 days after tumour cells 
inoculation) and the tumour was palpable, transplanted 
mice received 100 μl intraperitoneal injections of cisplatin 
(4 mg/kg) [35] or vehicle (phosphate buffer saline - PBS) 
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three times every other day. When indicated, B16-W6_
pSIL10 and B16-F1_B1A transplanted mice also received 
15 μl injection in the peritumoural area of chloroquine 
diphosphate (30 mM) [49, 51] or vehicle (PBS). Tumour 
growth was monitored every 2-3 days by means of 
external calliper measurements and volume calculation 
(length x width2/2), until mice reached IACUC euthanasia 
criteria, as for instance clinical signs of tumour or when 
tumour size exceeded 10% of body weight (ca. 1500 mm3 
tumour volume) [35, 37, 38]. The mice were also observed 
to determine the duration of survival for each group 
using the Kaplan-Meier estimator (median survival). 
When indicated, mice were sacrificed when tumour size 
reached ca. 500 mm3 volume, and tumour collected for 
further analysis (i.e. TUNEL assay, Transmission electron 
microscopy analysis, and fluorescence microscopy).
TUNEL assay
The collected melanoma transplants were fixed in 
ice cold 4% paraformaldehyde before being rinsed in PBS 
and cryo-protected overnight in 30% sucrose. Tissues were 
then embedded in O.C.T. Compound (Sakura, AJAlphen 
aan den Rijn, The Netherlands) and cut in a CM1850 
UV cryostat (Leica Biosystems, Wetzlar, Germany). 
At least 5 cryosections (6 μm) were obtained from each 
tumour and assayed for apoptosis by the TUNEL method 
(DeadEnd Fluorometric TUNEL System; Promega, 
Milano, Italy), according to the manufacturer’s protocol. 
After DAPI counterstaining, samples were mounted 
with Vectashield (Vector Laboratories, Burlingame, CA, 
USA) and examined using a DMI4000 B automated 
inverted microscope equipped with a DCF310 digital 
camera (Leica Microsystems, Wetzlar, Germany). Image 
acquisition was controlled by the Leica LAS AF software.
Flow cytometry
Apoptotic mouse and human melanoma cells were 
evaluated by flow cytometry as described previously 
[38, 78-81]. Cells were incubated with 1 μg/ml Annexin 
V-FITC (to assess the phosphatidylserine exposure on 
the outer leaflet of the plasma membrane) and 2 μg/ml 
PI (DNA-binding probe) for 15 min at 4°C before being 
analysed by flow cytometry using Gallios Flow Cytometer 
(Beckman-Coulter, Brea, CA, USA) and the software FCS 
Express 4 (De Novo System, Portland, OR, USA). 
MTT assay
Using published protocols [38, 80, 82-84], cell 
viability of mouse and human melanoma cells was 
evaluated by MTT analysis. Each experimental condition 
was replicated in 8 wells. Cells were then washed and 
fresh medium containing MTT (0.5 mg/ml) was added in 
each well. After 4 h incubation at 37 °C, the supernatant 
was gently removed and formazan crystals were dissolved 
in DMSO. Absorbance was recorded at 570 nm with 
correction at 690 nm using a Glomax Multi Detection 
System microplate reader (Promega, Milano, Italy). 
A-SMase activity assay
As previously published [37], cells were 
homogenised in the acid lysis buffer (50 mM sodium 
acetate, 1% Triton X-100, 1 mM EDTA, pH 5) with freshly 
added protease inhibitor cocktail (cOmplete; Roche 
Diagnostics, Milano, Italy). Sphingomyelinase activity 
was measured using the Amplex Red Sphingomyelinase 
Assay Kit (Life Technologies, Monza, Italy), as described 
in the manufacturer’s protocol.
Protein isolation and western blotting
Mouse melanoma cells were homogenised for 
10 min at 4°C in RIPA lysis buffer, containing 50 mM 
Tris-HCl (pH 7.4), 150 mM NaCl, 1% NP-40, 1% 
sodium deoxycholate, 1 mM EDTA and 0.1% sodium 
dodecyl sulphate (SDS). Buffers were supplemented 
with a cocktail of protease and phosphatase inhibitors 
(cOmplete and PhosSTOP; Roche Diagnostics, Milano, 
Italy). Protein concentration was determined using the 
Bicinchoninic acid assay (ThermoFisher Scientific, 
Waltham, MA, USA). SDS and β-mercaptoethanol were 
added to samples before boiling, and equal amounts of 
proteins (40 μg/lane) were separated by 4-20% SDS-
polyacrylamide gel electrophoresis (Criterion TGX 
Stain-free precast gels and Criterion Cell system; Bio-
Rad, Hercules, CA, USA). Proteins were then transferred 
onto nitrocellulose membrane using a Bio-Rad Trans-
Blot Turbo System. The membranes were probed using 
the following primary antibodies: rabbit polyclonal anti-
LC3B, anti-p62/SQSTM1 (Sigma-Aldrich, Saint Louis, 
MO, USA), anti-phospho-Akt (Ser473), anti-phospho-S6 
ribosomal protein (Ser240/244), anti-phospho-Ulk1 
(Ser757), and rabbit monoclonal anti-cleaved caspase 
3 (Cell Signaling Technology, Danvers, MA, USA). 
After the incubation with the appropriate horseradish-
peroxidase (HRP)-conjugated secondary antibody (Cell 
Signaling Technology, Danvers, MA, USA), bands were 
visualised using the Clarity Western ECL substrate with a 
ChemiDoc MP imaging system (Bio-Rad, Hercules, CA, 
USA). To monitor for potential artefacts in loading and 
transfer among samples in different lanes, the blots were 
routinely treated with the Restore Western Blot Stripping 
Buffer (ThermoFisher Scientific, Waltham, MA, USA) 
and re-probed with the rabbit polyclonal anti-GAPDH 
(FL-335) primary antibody (Santa Cruz Biotechnology, 
Dallas, TX, USA). When appropriate, primary rabbit 
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polyclonal Akt, monoclonal S6 ribosomal protein (54D2), 
and monoclonal Ulk1 (D8H5) antibodies (Cell Signaling 
Technology, Danvers, MA, USA) that recognise the 
protein independently of its phosphorylation state were 
also used in reprobing experiments. Bands were quantified 
for densitometry [52] using the Image Lab software (Bio-
Rad, Hercules, CA, USA).
Transmission electron microscopy
The collected melanoma transplants were reduced 
into smaller blocks and stored overnight at 4°C in a 
fixative solution containing 2% formaldehyde and 2% 
glutaraldehyde in 0.1 M sodium cacodylate buffer, pH 
7.3. Fixed specimens were washed in cacodylate buffer 
and postfixed at 0°C for 1.5 h in 2% osmium tetroxide. 
The samples were washed in distilled water, stained in 
block in 2% aqueous uranyl acetate, dehydrated through 
an ascending series of ethanol and embedded in Araldite 
resin. For ultrastructural observations at least 5 ultra-thin 
sections (60-90 nm) were obtained from each tumour. 
Sections were collected on 100-mesh grids, counterstained 
with lead citrate and photographed (magnification 2500 
x) with a EM 10 electron microscope (Carl Zeiss, 
Oberkochen, Germany). Micrographs were scanned in a 
flat-bed scanner and images were merged. 
Fluorescence microscopy
Using published protocols for immunofluorescence 
of melanoma transplants [38], 6 μm cryosections were 
treated with citrate buffer for antigen retrieval. Tissue 
auto-fluorescence was quenched with 0.1 M glycine-PBS 
for 10 min. Sections were then incubated with blocking 
solution containing 10% goat serum and 1% BSA (30 min) 
before 1 h staining with the rabbit polyclonal anti-p62/
SQSTM1 primary antibody (Sigma-Aldrich, Saint Louis, 
MO, USA) in blocking solution supplemented with 0.1% 
saponin. For fluorescent detection Alexa Fluor 546 dye-
conjugated anti-rabbit IgG (Life Technologies, Monza, 
Italy) was used. Tissue sections were rinsed and coverslips 
added in the mounting medium containing DAPI. At least 
5 tissue sections were obtained from each tumour. Images 
were acquired with a DMI4000 B automated inverted 
microscope as specified above. Immuno-reactivity was 
quantified with ImageJ software (http://rsbweb.nih.gov/
ij/). In particular, the extent of staining of each section was 
calculated as integrated optical density, which is equal to 
the area × average density of image occupied by immune-
reactivity and represented in graph.
Statistics
Tumour growth was analysed using two-way 
ANOVA, followed by the Bonferroni post-test. pEC
50
 
was determined by non-linear regression curve analysis 
of the concentration-effect responses. Differences in 
pEC
50
 values among concentration-response curves were 
calculated with the F test. For the other experiments, 
statistical significance of data between the groups 
was evaluated using unpaired Student’s t-test (single 
comparisons) or one-way ANOVA followed by the 
Newman-Keuls post-test (multiple comparisons). When 
indicated, data belonging from different experiments 
were represented and averaged in the same graph. The 
GraphPad Prism software package (Graph Software, San 
Diego, CA, USA) was used. The results were expressed as 
means ± SEM of the indicated n values.
Chemicals
Iscove’s modified Dulbecco’s medium, Hepes, FBS, 
PBS, glutamine, penicillin/streptavidin, were purchased 
from Euroclone (Pero, Italy). Cisplatin (Cisplatino Teva) 
was from Teva Pharma Italia (Milano, Italy). Human 
A-SMase (Recombinant Human SMPD1, His-tagged) 
was purchased from Creative BioMart (Shirley, NY, 
USA). Annexin V-Fluorescein Isothiocianate (FITC) and 
PI were obtained from Life Technologies (Monza, Italy) 
and eBioscience (San Diego, CA, USA), respectively. All 
other reagents were purchased from Sigma-Aldrich (Saint 
Louis, MO, USA).
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